Buzz Health reported a behavioral threshold for prescription abandonment: when out-of-pocket costs rise to $35, fill rates drop sharply. The study found 89% of respondents would fill at a $15 cost, but that rate fell to 53% at $35, with abandonment climbing further at higher price points. The findings position affordability as a day-to-day adherence risk, not only a specialty-drug problem, highlighting how modest increases can prevent patients from starting therapy. The report also showed nearly half of respondents had previously walked away from a prescription due to cost. For pharma and health-plan stakeholders, the data support a renewed focus on pricing design, benefit engineering, and affordability measures—since adherence behavior appears to pivot around a relatively low threshold.